17628-73-8

Basic information

• Product Name: (R)-1,1,1-TRIFLUORO-2-PROPANOL
• Synonyms: (R)-1,1,1-TRIFLUORO-2-PROPANOL;(R)-1,1,1-TRIFLUOROISOPROPANOL;(R)-1,1,1-Trifluoropropan-2-ol;(R)-1,1,1-Trifluoro-2-propanol 97%;(2R)-1,1,1-Trifluoropropan-2-ol;2-Propanol, 1,1,1-trifluoro-, (2R)-;(R)-1,1,1-TRIFLUOROPROPAN-2-OL(WXFC0140)
• CAS NO: 17628-73-8
• Molecular Formula: C₃H₅F₃O
• Molecular Weight: 114.07
• EINECS: 206-240-4
• Mol File: 17628-73-8.mol
• Article Data: 25

Chemical Properties

• Boiling Point: 67.0±35.0 °C(Predicted)
• Flash Point: 18℃
• Appearance: /
• Density: 1.235±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.53±0.20(Predicted)
• CAS DataBase Reference: (R)-1,1,1-TRIFLUORO-2-PROPANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1,1,1-TRIFLUORO-2-PROPANOL(17628-73-8)
• EPA Substance Registry System: (R)-1,1,1-TRIFLUORO-2-PROPANOL(17628-73-8)

Safety Data

• Hazard Codes: F,Xi
• Statements: 11-36/37/38
• Safety Statements: 16-26-33
• RIDADR: UN 1987BE 3 / PGII
• WGK Germany: 3
• Hazardous Substances Data: 17628-73-8(Hazardous Substances Data)

Usage

General Description

(R)-1,1,1-TRIFLUORO-2-PROPANOL is a chemical compound with the molecular formula C3H5F3O. It is a colorless, volatile liquid that is commonly used as a solvent and reagent in organic synthesis. This chemical is primarily utilized in the pharmaceutical and agricultural industries, as well as in the production of fluorinated compounds. It is also used as a precursor for the synthesis of various chemicals and pharmaceutical intermediates. Due to its fluorinated structure, (R)-1,1,1-TRIFLUORO-2-PROPANOL exhibits unique chemical and physical properties that make it valuable in a range of applications. However, it should be handled with care as it can be harmful if ingested or inhaled, and may cause irritation to the eyes and skin.

Upstream product

• 421-50-1 1,1,1-trifluoro-2-propanone 
• 359-41-1 1,1,1-trifluoro-2,3-epoxypropane 
• 130025-34-2 (S)-2-trifluoromethyl-oxirane 
• 67-56-1 methanol 
• 374-01-6 1,1,1-trifluoroisopropanol 
• 18454-30-3 (+)-3-(1-trifluoromethylethoxy)propionic acid 
• 88378-50-1 (S)-(+)-1-Bromo-3,3,3-trifluoro-2-propanol 
• 143142-90-9 (2R)-2-(trifluoromethyl)oxirane 

Downstream Products

• 869569-63-1 C₁₀H₈ClF₃O₃ 
• 845616-82-2 5-methane-sulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-benzoic acid 
• 952508-26-8 2-[4-(5-{3-methyl-4-[(1R)-2,2,2-trifluoro-1-methylethoxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indol-1-yl]acetamide 
• 1224933-70-3 2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-benzoic acid 
• 1246442-51-2 carbonic acid 4-nitro-phenyl ester (S)-2,2,2-trifluoro-1-methyl-ethyl ester 
• 1252634-15-3 (2S,4R)-4-[2-Chloro-4-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-benzenesulfonyl]-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl Ester 2-methyl Ester 
• 1292278-82-0 4-((R)-2,2,2-trifluoro-1-methyl-ethoxy)-phenylamine 
• 1364677-75-7 5-(4-chloro-3-(4-chloro-phenyl)-2-(S)-2,2,2-trifluoro-1-methyl-ethoxy)-pyridine 
• 1364677-63-3 6-(4-chloro-phenyl)-5-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-pyrazine-2-carboxylic acid methyl ester 
• 1374674-98-2 4-{(S)-3-[2-chloro-4-((S)-2,2,2-trifluoro-1-methyl-1-ethoxy)-benzenesulfonyl]-pyrrolidin-1-yl}-6-trifluoromethyl-pyrimidine-2-carbonitrile 
• 1415818-17-5 (R)-1,1,1-trifluoropropan-2-yl 4-((1r,4r)-4-(3-iodopyridin-4-yloxy)cyclohexyloxy)piperidine-1-carboxylate 
• 1415818-05-1 (R)-1,1,1-trifluoropropan-2-yl 4-((1r,4r)-4-(3-cyanopyridin-4-yloxy)cyclohexyloxy)piperidine-1-carboxylate 

Relevant articles and documents

ION CHANNEL MODULATORS

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

ION CHANNEL MODULATORS

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.